GSK submits lupus drug for EU approval

06/7/2010 | Reuters

GlaxoSmithKline submitted a marketing application to the European Medicines Agency for its lupus drug candidate Benlysta. The drugmaker, which co-develops Benlysta with Human Genome Sciences, also plans to file for FDA approval of the treatment later this month.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI